This round of financing will be used for the company's vascular intervention robot research and development iteration, product indication expansion and accelerated clinical advancement.
At the same time, BMS has signed a strategic cooperation agreement with QIC Bridge. Based on the continuous empowerment of resources in the field of vascular intervention, Guichuang Tongqiao will accelerate the product development, clinical cooperation, registration filing and commercialization progress of BMS's vascular interventional robot, so as to achieve synergistic development of both parties' products and business, and to satisfy the wider clinical needs in vascular interventional surgery.
Microasia Medical Technology Co., Ltd. was founded in February 2021, is a high-tech enterprise dedicated to international cutting-edge vascular interventional surgical robots. The company's main product, minimally invasive vascular interventional surgical robot, is at the international advanced and domestic leading level. in April 2021, the new generation of surgical robots developed by MicroAsia Medical successfully conducted animal experiments at Fu Wai Hospital in Beijing, and received unanimous favorable comments from the country's top cardiovascular experts.
In the field of vascular interventional surgical robots, BEA Medical is one of the few remarkable teams in China with more than 10 years of R&D experience. The new generation of vascular interventional robots launched by BMS can simultaneously perform coronary, neurological and peripheral procedures for imaging and interventional therapy.
Compared with other products in the overseas market, BEA's robotic products are able to perform the entire procedure with a robot, which significantly increases the number of clinical application scenarios.
In terms of core technology, BMS has a new and original delivery technology, which has achieved breakthrough upgrades in key areas such as delivery precision, stability and safety, and can fully meet the needs of doctors in interventional surgery, and the products have been recognized by a number of top experts in China.
In the future, BMS will continue to plow into product upgrading, continue to improve product application capabilities and key technology breakthroughs, combine surgical robots with telemedicine to create an integrated platform for vascular interventional telemedicine, and contribute to the construction of vascular interventional telemedicine system.
Dr. Zhao Zhong, Chairman of GCTC, said: MicroAsia Medical is a leader in the field of vascular interventional surgical robots in China, and has a profound accumulation of technology and rich R&D experience in the integration of medicine and industry. The breakthrough technology of Micro-Asia Medical's surgical robotic products is expected to form a synergistic effect with Guichuang Tongqiao's peripheral and neurological interventional products, and to realize the technological innovation of vascular interventional procedures to the benefit of doctors and patients. We believe that this strategic investment will help the company to build a full program of vascular disease treatment platform, and further enhance the market competitiveness of Guichuang Tongqiao.
Ma Jinbo, Vice President of Investment of Boyuan Capital, said, "Vascular interventional robots have clinical, commercial and social values, and are a very worthwhile and sustainable product segment in the medical technology field. We believe that MicroAsia Medical's in-depth understanding of the clinical application of robots and its ability to iterate on breakthrough technologies will enable it to become a leading company in the field of vascular interventional surgery robots in China. Boyuan Capital and GCTB will each utilize their respective strengths in the capital market and industry to work together with MicroAsia Medical*** to continue to address unmet clinical needs with breakthrough innovative technologies, and to disrupt the future of vascular interventional surgery with scientific and technological innovations.
The founder of MicroMed said, "For more than 10 years, the founding team of MicroMed has been firmly committed to solving clinical needs as the core, underlying technology research and development as the cornerstone, and creating disruptive products as the mission, and the years of intensive cultivation have achieved remarkable product results. BEA Medical will not be satisfied with the current results, and will continue to make efforts in product iteration and technology research and development, and continue to explore the technological breakthroughs of vascular interventional robots in more complex procedures and diversified applications in the field of telemedicine, in order to satisfy the needs of a wide range of doctors and patients to improve the efficacy of interventional procedures.
Attached
For more information on the project, please go to.